These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 38033416)

  • 1. Metastatic Salivary Duct Carcinoma with ERBB2 Amplification and Sequential Response to Ado-Trastuzumab Emtansine and Neratinib: A Case Report.
    Asper N; Roth KS; Hany TF; Salzberg SP; Tinguely M; Kadvany Y; Trojan A
    Case Rep Oncol; 2023; 16(1):1500-1507. PubMed ID: 38033416
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Second-Line Treatment of HER2-Positive Salivary Gland Tumor: Ado-Trastuzumab Emtansine (T-DM1) after Progression on Trastuzumab.
    Corrêa TS; Matos GDR; Segura M; Dos Anjos CH
    Case Rep Oncol; 2018; 11(2):252-257. PubMed ID: 29867432
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Metastatic Parotid Gland Carcinoma With ERBB2 Amplification With Complete Response to Fam-Trastuzumab Deruxtecan.
    Shukla ND; Chiang RS; Colevas AD
    J Natl Compr Canc Netw; 2022 Feb; 20(2):102-104. PubMed ID: 35130504
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Case series of docetaxel, trastuzumab, and pertuzumab (DTP) as first line anti-HER2 therapy and ado-trastuzumab emtansine (T-DM1) as second line for recurrent or metastatic HER2-positive salivary duct carcinoma.
    Uijen MJM; Lassche G; van Engen-van Grunsven ACH; Driessen CML; van Herpen CML
    Oral Oncol; 2022 Feb; 125():105703. PubMed ID: 34995931
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase 2 multicenter study of docetaxel-PM and trastuzumab-pkrb combination therapy in recurrent or metastatic salivary gland carcinomas.
    Lee J; Park S; Jung HA; Lee SH; Seo S; Kim SB; Kim JW; Lee KW; Kang EJ; Kim JW; Choi YJ; Shim BY; An HJ; Park LC; Shin SH; Kim JJ; Oh SY; Kim MK; Ahn MJ
    Cancer; 2023 Oct; 129(19):2966-2974. PubMed ID: 37246414
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Androgen Deprivation Therapy for Patients with Androgen-Receptor-Positive Metastatic Salivary Duct Carcinoma: A Case Report and Review of the Literature.
    You Y; Wang P; Wan X; Xu L; Gong Y; Zhang W
    Onco Targets Ther; 2021; 14():3481-3486. PubMed ID: 34093024
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Case report: ado-trastuzumab as second-line treatment in HER2 positive salivary duct carcinoma.
    Taha T; Billan S
    Anticancer Drugs; 2022 Jan; 33(1):e760-e763. PubMed ID: 34387606
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ERBB2 Amplification and HER2 Expression in Salivary Duct Carcinoma: Evaluation of Scoring Guidelines and Potential for Expanded Anti-HER2 Therapy.
    McAfee JL; Hoda RS; Hoyle C; McCoy L; Sprague C; Reddy CA; Koyfman SA; Geiger JL; Komforti MK; Griffith CC
    Mod Pathol; 2023 Oct; 36(10):100273. PubMed ID: 37423585
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Metastatic salivary duct carcinoma in cardiac and pleural effusions: A case report with immunocytochemical analysis for androgen receptor and HER2.
    Ito H; Ishida M; Sando K; Okano K; Ebisu Y; Fujisawa T; Iwai H; Tsuta K
    Mol Clin Oncol; 2019 Jan; 10(1):78-82. PubMed ID: 30655980
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeted Approaches Applied to Uncommon Diseases: A Case of Salivary Duct Carcinoma Metastatic to the Brain Treated with the Multikinase Inhibitor Neratinib.
    Sorenson KR; Piovezani Ramos G; Villasboas Bisneto JC; Price K
    Case Rep Oncol; 2017; 10(2):726-731. PubMed ID: 28878657
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Salivary duct carcinoma responding to trastuzumab-based therapy: case report and review of the literature.
    Krishnamurthy J; Krishnamurty DM; Baker JJ; Zhen W; Lydiatt D; Ganti AK
    Head Neck; 2013 Dec; 35(12):E372-5. PubMed ID: 23765450
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Androgen Deprivation Therapy for Intracranial Metastasis of a Salivary Duct Carcinoma: Case Report.
    Rösch M; Bieg C; Savic S; Buess M
    Case Rep Oncol; 2023; 16(1):109-115. PubMed ID: 36844935
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel therapeutic targets in salivary duct carcinoma uncovered by comprehensive molecular profiling.
    Gargano SM; Senarathne W; Feldman R; Florento E; Stafford P; Swensen J; Vranic S; Gatalica Z
    Cancer Med; 2019 Dec; 8(17):7322-7329. PubMed ID: 31609094
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinicopathological features and treatment outcomes of the rare, salivary duct carcinoma of parotid gland.
    Al-Qahtani KH; Tunio MA; Bayoumi Y; Gurusamy VM; Bahamdain FA; Fatani H
    J Otolaryngol Head Neck Surg; 2016 May; 45(1):32. PubMed ID: 27184361
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Salivary duct carcinoma--a highly aggressive salivary gland tumor with HER-2/neu oncoprotein overexpression.
    Skálová A; Stárek ; Kucerová V; Szépe P; Plank L
    Pathol Res Pract; 2001; 197(9):621-6. PubMed ID: 11569926
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Complete Response to Trastuzumab-Based Chemotherapy in a Patient with Human Epidermal Growth Factor Receptor-2-Positive Metastatic Salivary Duct Carcinoma ex Pleomorphic Adenoma.
    Kadowaki S; Yatabe Y; Hirakawa H; Komori A; Kondoh C; Hasegawa Y; Muro K
    Case Rep Oncol; 2013; 6(3):450-5. PubMed ID: 24163659
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adjuvant Treatment of the Salivary Duct Carcinoma with Her2 Overexpression.
    Berendika J; Jungić S; Tubić B; Malčić Kecman G; Rakita I; Gojković Z; Vještica M; Nikić G; Babić B
    Case Rep Oncol; 2021; 14(1):610-615. PubMed ID: 33976642
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pathological response of salivary duct carcinoma to trastuzumab and docetaxel therapy.
    Ueki Y; Tada Y; Togashi T; Kawakita D; Nagao T; Sato Y
    Int Cancer Conf J; 2016 Jul; 5(3):150-153. PubMed ID: 31149444
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combination Chemohormonal Therapy in Metastatic Salivary Duct Carcinoma.
    Jeong ISD; Moyers J; Thung I; Thinn MM
    Am J Case Rep; 2020 Jun; 21():e925181. PubMed ID: 32601266
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Salivary duct carcinoma: evaluation of treatment and outcome in a tertiary referral institute.
    Beck ACC; Lohuis PJFM; Al-Mamgani A; Smit LA; Klop WMC
    Eur Arch Otorhinolaryngol; 2018 Jul; 275(7):1885-1892. PubMed ID: 29785551
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.